Al in Pathology Market - Global Forecast to 2030
商品番号 : SMB-39671
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年5月 |
| ページ数 | 320 |
| 図表数 | 323 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
- 製品開発/イノベーション: 病理学における AI 市場における今後の技術、研究開発活動、新製品および新サービスの発売に関する詳細な洞察。
- 市場開発：提供内容、ニューラルネットワーク、機能、ユースケース、エンドユーザー、地域別に、収益性の高い新興市場に関する包括的な情報を提供します。
- 市場多様化：製品ポートフォリオ、成長地域、最近の動向、市場への投資に関する包括的な情報を提供します。
- 競合評価：主要企業の市場シェア、成長戦略、製品提供、および能力に関する詳細な評価を提供します。
The global AI in pathology market is expected to reach USD 347.39 million by 2030 from USD 107.43 million in 2025 at a high CAGR of 26.5% during the forecast period. According to the Personalized Medicine Coalition Report 2022, in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases. Among the newly approved treatments are seven cancer drugs and three targeting other diseases and conditions. About 47% of these approved personalized therapies were indicated for treating cancer.
病理学におけるAI活用の世界市場は、予測期間中に26.5%の高いCAGR（年平均成長率）を維持し、2025年の1億743万米ドルから2030年には3億4,739万米ドルに達すると予想されています。パーソナライズ医療連合レポート2022によると、2023年にはFDA（米国食品医薬品局）が希少疾患患者向けの新たなパーソナライズ治療を16件承認しました。新たに承認された治療の中には、抗がん剤が7件、その他の疾患や病状を標的とした治療が3件含まれています。承認されたパーソナライズ治療の約47%は、がん治療を適応としていました
By use case, the drug discovery segment accounted for the largest share in 2024.
In 2024, the drug discovery segment accounted for the largest share of the AI in pathology market. Booming pharmaceutical & biotechnology R&D expenditure, the growing high-throughput screening & imaging, the increasing use of AI algorithms in pathology image analysis for the identification & classification of diseases, and the capability of AI to speed up the development of new therapeutics are expected to boost the market.
In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the AI in pathology market, by end user.
In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest market share due to advancements in drug discovery & development and the increasing use of AI in pathology for drug toxicology testing. Biotechnology companies use AI-based digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.
North America held the largest market share in 2024.
In 2024, North America accounted for the largest market share in the AI in pathology market due to strong investment in research & development and advanced healthcare infrastructure, which enables the use of high-tech machinery. The large patient pool and data availability help create a large database, which can be used to train the AI for higher accuracy and efficiency.
The breakdown of primary participants is as mentioned below:
- By Company Type – Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
- By Designation – C-level: 42%, Director-level: 31%, and Others: 27%
- By Region – North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%
Key Players
The key players in the AI in pathology market include Koninklijke Philips N.V. (Netherlands), F. Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel).
Research Coverage
The report estimates the market size and future growth potential of various market segments based on offering, neural network, use case, end user, function, and region. It also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms and new entrants/smaller firms to gauge the market’s pulse, which, in turn, would help them garner a higher share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of key drivers (development of CNNs and advanced AI models, Integration of AI into multiplex imaging, increasing cases of misdiagnoses in patients, benefits of AI-augmented telepathology, advancements in deep learning & image processing) restraints (high cost of digital pathology systems, limited AI expertise and varied regulatory guidelines for medical software, interoperability issues with legacy systems), opportunities (increasing demand for personalized medicine, integration of multi-omics data, and predictive analytics for disease progression) challenges (insufficient data for AI algorithms, data privacy, and ethical concerns, challenges associated with interpretability of AI models) influencing the growth of the AI in pathology market
- Product Development/Innovation: Detailed insights into upcoming technologies, research & development activities, and new product & service launches in the AI in pathology market
- Market Development: Comprehensive information on the lucrative emerging markets by offering, neural network, function, use case, end user, and region
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players
Table of Contents
1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.3 STUDY SCOPE 29
1.3.1 MARKET SEGMENTATION AND GEOGRAPHIC SPREAD 29
1.3.2 INCLUSIONS & EXCLUSIONS 30
1.4 YEARS CONSIDERED 31
1.5 CURRENCY CONSIDERED 31
1.6 KEY STAKEHOLDERS 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 35
2.1.2 PRIMARY DATA 35
2.1.2.1 Revenue share analysis illustration 37
2.2 MARKET SIZE ESTIMATION 38
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 44
2.4 RESEARCH ASSUMPTIONS 45
2.5 RESEARCH LIMITATIONS 45
2.5.1 METHODOLOGY-RELATED LIMITATIONS 45
2.5.2 SCOPE-RELATED LIMITATIONS 45
2.6 RISK ASSESSMENT 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 51
4.1 KEY OPPORTUNITIES FOR PLAYERS IN AI IN PATHOLOGY MARKET 51
4.2 AI IN PATHOLOGY MARKET: REGIONAL MIX 52
4.3 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER AND KEY COUNTRY/REGION 53
4.4 GEOGRAPHIC GROWTH OPPORTUNITIES 54
5 MARKET OVERVIEW 55
5.1 INTRODUCTION 55
5.2 MARKET DYNAMICS 55
5.2.1 DRIVERS 56
5.2.1.1 Development of CNNs and advanced AI models 56
5.2.1.2 Integration of AI into multiplex imaging 56
5.2.1.3 Increasing cases of misdiagnoses in patients 57
5.2.1.4 Benefits of AI-augmented telepathology 57
5.2.1.5 Advancements in deep learning & image processing 58
5.2.2 RESTRAINTS 58
5.2.2.1 High cost of digital pathology systems 58
5.2.2.2 Limited AI expertise and varied regulatory guidelines for medical software 59
5.2.2.3 Inadequate interoperability issues with legacy systems 59
5.2.3 OPPORTUNITIES 60
5.2.3.1 Increasing demand for personalized medicines 60
5.2.3.2 Integration of multi-omics data 60
5.2.3.3 Predictive analytics for disease progression 61
5.2.4 CHALLENGES 61
5.2.4.1 Insufficient data for AI algorithms 61
5.2.4.2 Data privacy and ethical concerns 61
5.2.4.3 Challenges associated with interpretability of AI models 62
5.3 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63
5.4 INDUSTRY TRENDS 63
5.4.1 EVOLUTION OF AI IN PATHOLOGY 63
5.5 ECOSYSTEM ANALYSIS 64
5.6 VALUE CHAIN ANALYSIS 67
5.7 TECHNOLOGY ANALYSIS 68
5.7.1 KEY TECHNOLOGIES 68
5.7.1.1 Machine learning (ML) and artificial intelligence (AI) 68
5.7.1.2 Computer vision 68
5.7.2 COMPLEMENTARY TECHNOLOGIES 69
5.7.2.1 Cloud computing 69
5.7.3 ADJACENT TECHNOLOGIES 69
5.7.3.1 Telepathology 69
5.8 REGULATORY LANDSCAPE 70
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
5.8.2 REGULATIONS, BY REGION 70
5.8.2.1 North America 70
5.8.2.1.1 US 70
5.8.2.1.2 Canada 71
5.8.2.2 Europe 72
5.8.2.3 Asia Pacific 73
5.8.2.3.1 Japan 73
5.8.2.3.2 China 74
5.9 PRICING ANALYSIS 75
5.9.1 AVERAGE SELLING PRICE TREND, BY REGION 75
5.9.2 INDICATIVE PRICING ANALYSIS, BY OFFERING 75
5.10 PORTER’S FIVE FORCES ANALYSIS 76
5.10.1 THREAT FROM NEW ENTRANTS 77
5.10.2 THREAT FROM SUBSTITUTES 77
5.10.3 BARGAINING POWER OF SUPPLIERS 77
5.10.4 BARGAINING POWER OF BUYERS 77
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.11 PATENT ANALYSIS 78
5.11.1 PATENT PUBLICATION TRENDS FOR AI IN PATHOLOGY SOLUTIONS 78
5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS 79
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 82
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 82
5.12.2 BUYING CRITERIA 83
5.13 END USER ANALYSIS 83
5.13.1 UNMET NEEDS OF END USERS 83
5.13.2 END USER EXPECTATIONS 84
5.14 KEY CONFERENCES AND EVENTS, 2025–2026 85
5.15 CASE STUDY ANALYSIS 86
5.15.1 CASE STUDY 1: PATBAL EMPLOYED PYTORCH FOR ITS HIGH-LEVEL PYTHONIC SYNTAX TO SUPPORT DIVERSE MODELING APPROACHES 86
5.15.2 CASE STUDY 2: KFBIO DEVELOPED KFBIO AI CERVICAL CANCER SCREENING SYSTEM TO STRENGTHEN CANCER DIAGNOSIS 86
5.15.3 CASE STUDY 3: RESEARCH TEAM FROM UNIVERSITY OF HELSINKI USED AIFORIA CREATE TO DEVELOP DEEP-LEARNING AI MODEL TO PREDICT PATIENT OUTCOMES 87
5.16 INVESTMENT & FUNDING SCENARIO 87
5.17 BUSINESS MODELS 88
5.18 IMPACT OF AI/GEN AI ON AI IN PATHOLOGY MARKET 88
5.18.1 KEY USE CASES 89
5.18.2 AI/GENERATIVE AI IMPLEMENTATION: CASE STUDY 90
5.18.2.1 Accelerated biomarker discovery and clinical trial optimization 90
5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 91
5.18.3.1 Drug discovery & development market 91
5.18.3.2 Medical imaging & diagnostics market 91
5.18.4 USER READINESS AND IMPACT ASSESSMENT 92
5.18.4.1 User readiness 92
5.18.4.1.1 Pharmaceutical companies 92
5.18.4.1.2 Biopharmaceutical companies 92
5.18.4.2 Impact assessment 92
5.18.4.2.1 User A: Pharmaceutical companies 92
5.18.4.2.1.1 Implementation 92
5.18.4.2.1.2 Impact 93
5.18.4.2.2 User B: Biopharmaceutical companies 93
5.18.4.2.2.1 Implementation 93
5.18.4.2.2.2 Impact 93
5.19 TRADE ANALYSIS 93
5.19.1 IMPORT SCENARIO 94
5.19.2 EXPORT SCENARIO 95
5.20 US 2025 TARIFF 96
5.20.1 INTRODUCTION 96
5.20.2 KEY TARIFF RATES 97
5.20.3 PRICE IMPACT ANALYSIS 98
5.20.4 IMPACT ON COUNTRY/REGION 98
5.20.4.1 US 98
5.20.4.2 Europe 99
5.20.4.3 Asia Pacific 100
5.20.5 IMPACT ON END USE INDUSTRIES 100
6 AI IN PATHOLOGY MARKET, BY OFFERING 101
6.1 INTRODUCTION 102
6.2 END-TO-END SOLUTIONS 102
6.2.1 INCREASING DEMAND FOR INTEGRATED WORKFLOWS IN HEALTHCARE MODELS TO DRIVE MARKET 102
6.3 NICHE POINT SOLUTIONS 103
6.3.1 GROWING FOCUS ON PRECISION MEDICINE AND TARGETED THERAPY RESEARCH TO PROPEL MARKET 103
6.4 TECHNOLOGY 104
6.4.1 RISING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO FUEL MARKET 104
6.5 HARDWARE 105
6.5.1 HIGH ADOPTION OF AI-BASED MICROSCOPES TO PROPEL MARKET 105
6.6 MICROSCOPES 107
6.6.1 NEED FOR AUTOMATED ANALYSIS OF TISSUE SAMPLES TO FUEL GROWTH 107
6.7 SCANNERS 108
6.7.1 IMPROVEMENTS IN IMAGE QUALITY AND PRECISION DIAGNOSTICS TO BOOST DEMAND 108
6.8 STORAGE SYSTEMS 110
6.8.1 NEED FOR STRUCTURED MODELS OF HIGH-RESOLUTION IMAGES TO SUPPORT MARKET GROWTH 110
7 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK 112
7.1 INTRODUCTION 113
7.2 CONVOLUTIONAL NEURAL NETWORKS (CNNS) 113
7.2.1 FOCUS ON PROVIDING HIGH-QUALITY IMAGE RECOGNITION AND OBJECTION DETECTION TO PROPEL MARKET 113
7.3 GENERATIVE ADVERSARIAL NETWORKS (GANS) 115
7.3.1 NEED FOR GENERATING ACCURATE SYNTHETIC PATHOLOGY IMAGES TO DRIVE MARKET 115
7.4 RECURRENT NEURAL NETWORKS (RNNS) 116
7.4.1 NEED FOR ANALYSIS OF SEQUENTIAL DATA AND TIME-DEPENDENT PATTERNS TO FUEL MARKET 116
7.5 OTHER NEURAL NETWORKS 118
8 AI IN PATHOLOGY MARKET, BY FUNCTION 119
8.1 INTRODUCTION 120
8.2 IMAGE ANALYSIS 121
8.2.1 DETECTION OF CELLULAR ANOMALIES AND DISEASE MARKERS TO FUEL UPTAKE 121
8.3 DIAGNOSTICS 122
8.3.1 RAPID PROCESSION OF AUTOMATED SAMPLES TO DRIVE MARKET 122
8.4 WORKFLOW MANAGEMENT 123
8.4.1 OPTIMIZATION OF LAB RESOURCES FOR HIGH-THROUGHPUT RESULTS TO FUEL UPTAKE 123
8.5 DATA MANAGEMENT 124
8.5.1 EMPHASIS ON ADVANCEMENTS IN DATA INTEGRATION AND PROCESSING TO BOOST DEMAND 124
8.6 PREDICTIVE ANALYTICS 125
8.6.1 GROWING FOCUS ON EARLY DIAGNOSIS OF DISEASES TO DRIVE MARKET 125
8.7 CDSS 126
8.7.1 PROVISION OF REAL-TIME INSIGHTS TO FUEL MARKET 126
8.8 AUTOMATED REPORT GENERATION 127
8.8.1 INCREASING DEMAND FOR QUALITY CONTROL TO DRIVE MARKET 127
8.9 QUALITY ASSURANCE TOOLS 128
8.9.1 RISING REGULATORY NEED TO ACCELERATE DEMAND FOR QUALITY ASSURANCE TOOLS TO BOOST GROWTH 128
9 AI IN PATHOLOGY MARKET, BY USE CASE 129
9.1 INTRODUCTION 130
9.2 DRUG DISCOVERY 130
9.2.1 TARGET IDENTIFICATION & SELECTION 133
9.2.1.1 Analysis of molecular and histological data for biomarker discovery to fuel market 133
9.2.2 TARGET VALIDATION 134
9.2.2.1 Increasing demand for precision medicines to drive market 134
9.2.3 HIT IDENTIFICATION & PRIORITIZATION 135
9.2.3.1 Growing requirement for rapid analysis and cost efficiency to fuel uptake 135
9.2.4 HIT-TO-LEAD IDENTIFICATION 136
9.2.4.1 Advancements in ML to support market growth 136
9.2.5 LEAD OPTIMIZATION 137
9.2.5.1 Growing focus on therapeutic efficacy to propel market 137
9.2.6 CANDIDATE SELECTION & VALIDATION 138
9.2.6.1 Critical requirement for regulatory approvals to drive market 138
9.3 DISEASE DIAGNOSIS & PROGNOSIS 139
9.3.1 INCREASING INCIDENCE OF CHRONIC DISEASES TO FUEL MARKET 139
9.4 CLINICAL WORKFLOW 140
9.4.1 STRUCTURED AUTOMATION OF EXTENSIVE VOLUME DATA TO DRIVE MARKET 140
9.5 TRAINING & EDUCATION 141
9.5.1 UTILIZATION OF DIGITAL PATHOLOGY SYSTEMS IN ACADEMIC INSTITUTES TO SUPPORT MARKET GROWTH 141
10 AI IN PATHOLOGY MARKET, BY END USER 143
10.1 INTRODUCTION 144
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 144
10.2.1 GROWING FOCUS ON TOXICOLOGY TESTING TO PROPEL MARKET 144
10.3 HOSPITALS & REFERENCE LABORATORIES 145
10.3.1 INCREASING NEED FOR EFFECTIVE DIAGNOSES OF INFECTIOUS DISEASES TO DRIVE GROWTH 145
10.4 ACADEMIC & RESEARCH INSTITUTES 147
10.4.1 GROWING INVESTMENTS IN LIFE SCIENCES RESEARCH TO SUPPORT DEMAND 147
11 AI IN PATHOLOGY MARKET, BY REGION 148
11.1 INTRODUCTION 149
11.2 NORTH AMERICA 149
11.2.1 MACROECONOMIC OUTLOOK 149
11.2.2 US 153
11.2.2.1 High healthcare expenditure and improvements in cloud computing platforms to propel market 153
11.2.3 CANADA 157
11.2.3.1 Increasing adoption of deep learning for advanced healthcare diagnostics to drive market 157
11.3 EUROPE 160
11.3.1 MACROECONOMIC OUTLOOK 160
11.3.2 UK 163
11.3.2.1 Increased focus on drug discovery and development to boost demand 163
11.3.3 GERMANY 166
11.3.3.1 Availability of funding for AI initiatives to fuel uptake 166
11.3.4 FRANCE 169
11.3.4.1 Increasing adoption of big data in healthcare computing to fuel uptake 169
11.3.5 ITALY 172
11.3.5.1 Digital transformation and innovation in healthcare to support market growth 172
11.3.6 SPAIN 175
11.3.6.1 Increased workforce shortage to fuel market 175
11.3.7 REST OF EUROPE 178
11.4 ASIA PACIFIC 181
11.4.1 MACROECONOMIC OUTLOOK 181
11.4.2 CHINA 185
11.4.2.1 Rising cases of infectious and chronic diseases to fuel demand 185
11.4.3 JAPAN 188
11.4.3.1 Advanced healthcare infrastructure to propel market 188
11.4.4 INDIA 191
11.4.4.1 Growing focus on healthcare digitization to boost demand 191
11.4.5 REST OF ASIA PACIFIC 195
11.5 LATIN AMERICA 198
11.5.1 MACROECONOMIC OUTLOOK 198
11.5.2 BRAZIL 201
11.5.2.1 Strategic investments for AI adoption to support market growth 201
11.5.3 MEXICO 204
11.5.3.1 Growth in pharmaceutical R&D to drive market 204
11.5.4 REST OF LATIN AMERICA 207
11.6 MIDDLE EAST & AFRICA 210
11.6.1 MACROECONOMIC OUTLOOK 210
11.6.2 GCC COUNTRIES 213
11.6.2.1 Increasing investments for expansion of technological expertise to support growth 213
11.6.3 REST OF MIDDLE EAST & AFRICA 216
12 COMPETITIVE LANDSCAPE 220
12.1 INTRODUCTION 220
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 220
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN PATHOLOGY MARKET 221
12.3 REVENUE ANALYSIS, 2020−2024 223
12.4 MARKET SHARE ANALYSIS, 2024 223
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 226
12.5.1 STARS 226
12.5.2 EMERGING LEADERS 226
12.5.3 PERVASIVE PLAYERS 226
12.5.4 PARTICIPANTS 226
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 228
12.5.5.1 Company footprint 228
12.5.5.2 Offering footprint 229
12.5.5.3 Use case footprint 230
12.5.5.4 End user footprint 231
12.5.5.5 Region footprint 232
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 233
12.6.1 PROGRESSIVE COMPANIES 233
12.6.2 RESPONSIVE COMPANIES 233
12.6.3 DYNAMIC COMPANIES 233
12.6.4 STARTING BLOCKS 233
12.6.5 COMPETITIVE BENCHMARKING 235
12.7 COMPANY VALUATION & FINANCIAL METRICS 236
12.7.1 FINANCIAL METRICS 236
12.7.2 COMPANY VALUATION 236
12.8 BRAND/PRODUCT COMPARISON 237
12.9 COMPETITIVE SCENARIO 237
12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 237
12.9.2 DEALS 239
12.9.3 OTHER DEVELOPMENTS 241
13 COMPANY PROFILES 242
13.1 KEY PLAYERS 242
13.1.1 KONINKLIJKE PHILIPS N.V. 242
13.1.1.1 Business overview 242
13.1.1.2 Products/Services offered 243
13.1.1.3 Recent developments 244
13.1.1.3.1 Deals 244
13.1.1.4 MnM view 244
13.1.1.4.1 Key strengths 244
13.1.1.4.2 Strategic choices 244
13.1.1.4.3 Weaknesses & competitive threats 244
13.1.2 F. HOFFMANN-LA ROCHE LTD. 245
13.1.2.1 Business overview 245
13.1.2.2 Products/Services offered 246
13.1.2.3 Recent developments 247
13.1.2.3.1 Product/Service launches & approvals 247
13.1.2.3.2 Deals 248
13.1.2.4 MnM view 248
13.1.2.4.1 Key strengths 248
13.1.2.4.2 Strategic choices 248
13.1.2.4.3 Weaknesses & competitive threats 248
13.1.3 HOLOGIC, INC. 249
13.1.3.1 Business overview 249
13.1.3.2 Products/Services offered 250
13.1.3.3 Recent developments 251
13.1.3.3.1 Product/Service launches & approvals 251
13.1.3.4 MnM view 251
13.1.3.4.1 Key strengths 251
13.1.3.4.2 Strategic choices 251
13.1.3.4.3 Weaknesses & competitive threats 251
13.1.4 AKOYA BIOSCIENCES, INC. 252
13.1.4.1 Business overview 252
13.1.4.2 Products/Services offered 253
13.1.4.3 Recent developments 254
13.1.4.3.1 Deals 254
13.1.4.4 MnM view 255
13.1.4.4.1 Key strengths 255
13.1.4.4.2 Strategic choices 255
13.1.4.4.3 Weaknesses & competitive threats 255
13.1.5 AIFORIA TECHNOLOGIES PLC 256
13.1.5.1 Business overview 256
13.1.5.2 Products/Services offered 257
13.1.5.3 Recent developments 258
13.1.5.3.1 Deals 258
13.1.5.4 MnM view 260
13.1.5.4.1 Key strengths 260
13.1.5.4.2 Strategic choices 260
13.1.5.4.3 Weaknesses & competitive threats 260
13.1.6 INDICA LABS INC. 261
13.1.6.1 Business overview 261
13.1.6.2 Products/Services offered 261
13.1.6.3 Recent developments 262
13.1.6.3.1 Product/Service launches & approvals 262
13.1.6.3.2 Deals 263
13.1.6.3.3 Expansions 265
13.1.7 OPTRASCAN 266
13.1.7.1 Business overview 266
13.1.7.2 Products/Services offered 266
13.1.7.3 Recent developments 267
13.1.7.3.1 Other developments 267
13.1.8 IBEX MEDICAL ANALYTICS LTD. 268
13.1.8.1 Business overview 268
13.1.8.2 Products/Services offered 268
13.1.8.3 Recent developments 269
13.1.8.3.1 Product/Service launches & approvals 269
13.1.8.3.2 Deals 270
13.1.9 MINDPEAK GMBH 272
13.1.9.1 Business overview 272
13.1.9.2 Products/Services offered 272
13.1.9.3 Recent developments 273
13.1.9.3.1 Product/Service launches & approvals 273
13.1.9.3.2 Deals 273
13.1.9.3.3 Other developments 274
13.1.10 TRIBUN HEALTH 275
13.1.10.1 Business overview 275
13.1.10.2 Products/Services offered 275
13.1.10.3 Recent developments 276
13.1.10.3.1 Deals 276
13.1.11 TECHCYTE, INC. 277
13.1.11.1 Business overview 277
13.1.11.2 Products/Services offered 277
13.1.11.3 Recent developments 278
13.1.11.3.1 Product/Service launches & approvals 278
13.1.11.3.2 Deals 278
13.1.11.3.3 Other developments 279
13.1.12 DEEP BIO INC. 280
13.1.12.1 Business overview 280
13.1.12.2 Products/Services offered 280
13.1.12.3 Recent developments 281
13.1.12.3.1 Deals 281
13.1.13 LUMEA INC. 282
13.1.13.1 Business overview 282
13.1.13.2 Products/Services offered 282
13.1.13.3 Recent developments 283
13.1.13.3.1 Deals 283
13.1.14 VISIOPHARM 284
13.1.14.1 Business overview 284
13.1.14.2 Products/Services offered 284
13.1.14.3 Recent developments 285
13.1.14.3.1 Product/Service launches & approvals 285
13.1.14.3.2 Expansions 285
13.1.15 AETHERAI 287
13.1.15.1 Business overview 287
13.1.15.2 Products/Services offered 287
13.1.15.3 Recent developments 288
13.1.15.3.1 Deals 288
13.1.16 AIOSYN 289
13.1.16.1 Business overview 289
13.1.16.2 Products/Services offered 289
13.1.16.3 Recent developments 290
13.1.16.3.1 Product/Service launches & approvals 290
13.1.16.3.2 Deals 291
13.1.16.3.3 Other developments 291
13.1.17 PAIGE AI, INC. 292
13.1.17.1 Business overview 292
13.1.17.2 Products/Services offered 292
13.1.17.3 Recent developments 293
13.1.17.3.1 Product/Service launches & approvals 293
13.1.17.3.2 Deals 295
13.1.17.3.3 Other developments 295
13.1.18 PROSCIA, INC. 296
13.1.18.1 Business overview 296
13.1.18.2 Products/Services offered 296
13.1.18.3 Recent developments 297
13.1.18.3.1 Product/Service launches & approvals 297
13.1.18.3.2 Deals 298
13.1.18.3.3 Other developments 298
13.1.19 PATHAI, INC. 299
13.1.19.1 Business overview 299
13.1.19.2 Products/Services offered 299
13.1.19.3 Recent developments 300
13.1.19.3.1 Product/Service launches & approvals 300
13.1.19.3.2 Deals 301
13.1.20 TEMPUS LABS, INC. 303
13.1.20.1 Business overview 303
13.1.20.2 Products/Services offered 304
13.1.20.3 Recent developments 304
13.1.20.3.1 Product/Service launches & approvals 304
13.2 OTHER PLAYERS 305
13.2.1 KONFOONG BIOINFORMATION TECH CO., LTD. 305
13.2.2 DOMORE DIAGNOSTICS AS 306
13.2.3 QRITIVE 306
13.2.4 DEEPATHOLOGY LTD 307
13.2.5 4D PATH INC. 308
14 APPENDIX 309
14.1 DISCUSSION GUIDE 309
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 316
14.3 CUSTOMIZATION OPTIONS 318
14.4 RELATED REPORTS 318
14.5 AUTHOR DETAILS 319
LIST OF TABLES
TABLE 1 EXCHANGE RATES, 2021–2024 31
TABLE 2 ROLE OF PLAYERS IN MARKET ECOSYSTEM 66
TABLE 3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 4 US FDA: MEDICAL DEVICE CLASSIFICATION 71
TABLE 5 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 71
TABLE 6 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 72
TABLE 7 EUROPE: CLASSIFICATION OF IVD DEVICES 72
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 74
TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES 74
TABLE 10 INDICATIVE PRICING ANALYSIS, BY OFFERING 75
TABLE 11 IMPACT OF PORTER’S FORCES 77
TABLE 12 JURISDICTION ANALYSIS OF TOP APPLICANTS IN AI IN PATHOLOGY MARKET 79
TABLE 13 KEY PATENTS IN AI IN PATHOLOGY MARKET 81
TABLE 14 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 82
TABLE 15 KEY BUYING CRITERIA, BY END USER 83
TABLE 16 UNMET NEEDS OF END USERS 84
TABLE 17 AI IN PATHOLOGY MARKET: END USER EXPECTATIONS 84
TABLE 18 LIST OF CONFERENCES AND EVENTS, 2025–2026 85
TABLE 19 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY,
2020–2023 (USD THOUSAND) 95
TABLE 20 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY,
2020–2023 (USD MILLION) 96
TABLE 21 RECIPROCAL TARIFF RATES ADJUSTED BY US 97
TABLE 22 TARIFF RATES FOR AI IN PATHOLOGY PRODUCTS 97
TABLE 23 EXPECTED CHANGE IN PRICES AND THEIR IMPACT ON END USER PRODUCTS DUE TO TARIFF IMPACT 98
TABLE 24 AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 102
TABLE 25 AI IN PATHOLOGY MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 103
TABLE 26 AI IN PATHOLOGY MARKET FOR NICHE POINT SOLUTIONS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 104
TABLE 27 AI IN PATHOLOGY MARKET FOR TECHNOLOGY, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 105
TABLE 28 AI IN PATHOLOGY MARKET FOR HARDWARE, BY TYPE, 2023–2030 (USD MILLION) 106
TABLE 29 AI IN PATHOLOGY MARKET FOR HARDWARE, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 106
TABLE 30 AI IN PATHOLOGY MARKET FOR MICROSCOPES, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 108
TABLE 31 AI IN PATHOLOGY MARKET FOR SCANNERS, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 109
TABLE 32 AI IN PATHOLOGY MARKET FOR STORAGE SYSTEMS, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 111
TABLE 33 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 113
TABLE 34 AI IN PATHOLOGY MARKET FOR CONVOLUTIONAL NEURAL NETWORKS,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 114
TABLE 35 AI IN PATHOLOGY MARKET FOR GENERATIVE ADVERSARIAL NETWORKS,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 116
TABLE 36 AI IN PATHOLOGY MARKET FOR RECURRENT NEURAL NETWORKS,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 117
TABLE 37 AI IN PATHOLOGY MARKET FOR OTHER NEURAL NETWORKS,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 118
TABLE 38 AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 120
TABLE 39 AI IN PATHOLOGY MARKET FOR IMAGE ANALYSIS, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 121
TABLE 40 AI IN PATHOLOGY MARKET FOR DIAGNOSTICS, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 122
TABLE 41 AI IN PATHOLOGY MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 123
TABLE 42 AI IN PATHOLOGY MARKET FOR DATA MANAGEMENT, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 124
TABLE 43 AI IN PATHOLOGY MARKET FOR PREDICTIVE ANALYTICS, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 125
TABLE 44 AI IN PATHOLOGY MARKET FOR CDSS, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 126
TABLE 45 AI IN PATHOLOGY MARKET FOR AUTOMATED REPORT GENERATION,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 127
TABLE 46 AI IN PATHOLOGY MARKET FOR QUALITY ASSURANCE TOOLS,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 128
TABLE 47 AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 130
TABLE 48 DRUG DISCOVERY APPLICATIONS FOR AI IN PATHOLOGY 131
TABLE 49 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,
2023–2030 (USD MILLION) 131
TABLE 50 AI IN PATHOLOGY MARKET FOR DRUG DISCOVERY, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 132
TABLE 51 AI IN PATHOLOGY MARKET FOR TARGET IDENTIFICATION & SELECTION,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 133
TABLE 52 AI IN PATHOLOGY MARKET FOR TARGET VALIDATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 134
TABLE 53 AI IN PATHOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 135
TABLE 54 AI IN PATHOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 136
TABLE 55 AI IN PATHOLOGY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 137
TABLE 56 AI IN PATHOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 138
TABLE 57 AI IN PATHOLOGY MARKET FOR DISEASE DIAGNOSIS & PROGNOSIS,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 140
TABLE 58 AI IN PATHOLOGY MARKET FOR CLINICAL WORKFLOW, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 141
TABLE 59 AI IN PATHOLOGY MARKET FOR TRAINING & EDUCATION, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 142
TABLE 60 AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 144
TABLE 61 AI IN PATHOLOGY MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY/REGION, 2023–2030 (USD MILLION) 145
TABLE 62 AI IN PATHOLOGY MARKET FOR HOSPITALS & REFERENCE LABORATORIES,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 146
TABLE 63 AI IN PATHOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES,
BY COUNTRY/REGION, 2023–2030 (USD MILLION) 147
TABLE 64 AI IN PATHOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION) 149
TABLE 65 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 151
TABLE 66 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING,
2023–2030 (USD MILLION) 151
TABLE 67 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION,
2023–2030 (USD MILLION) 152
TABLE 68 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 152
TABLE 69 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 153
TABLE 70 NORTH AMERICA: AI IN PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 153
TABLE 71 US: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 155
TABLE 72 US: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 155
TABLE 73 US: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 156
TABLE 74 US: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 156
TABLE 75 US: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 157
TABLE 76 CANADA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 158
TABLE 77 CANADA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 158
TABLE 78 CANADA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 159
TABLE 79 CANADA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 159
TABLE 80 CANADA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 160
TABLE 81 EUROPE: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 161
TABLE 82 EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 161
TABLE 83 EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 162
TABLE 84 EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 162
TABLE 85 EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 163
TABLE 86 EUROPE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 163
TABLE 87 UK: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 164
TABLE 88 UK: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 165
TABLE 89 UK: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 165
TABLE 90 UK: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 166
TABLE 91 UK: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 166
TABLE 92 GERMANY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 167
TABLE 93 GERMANY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 167
TABLE 94 GERMANY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 168
TABLE 95 GERMANY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 168
TABLE 96 GERMANY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 169
TABLE 97 FRANCE: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 170
TABLE 98 FRANCE: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 170
TABLE 99 FRANCE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 171
TABLE 100 FRANCE: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 171
TABLE 101 FRANCE: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 172
TABLE 102 ITALY: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 173
TABLE 103 ITALY: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 173
TABLE 104 ITALY: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 174
TABLE 105 ITALY: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 174
TABLE 106 ITALY: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 175
TABLE 107 SPAIN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 176
TABLE 108 SPAIN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 176
TABLE 109 SPAIN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 177
TABLE 110 SPAIN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 177
TABLE 111 SPAIN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 178
TABLE 112 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY OFFERING,
2023–2030 (USD MILLION) 179
TABLE 113 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY FUNCTION,
2023–2030 (USD MILLION) 179
TABLE 114 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 180
TABLE 115 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 180
TABLE 116 REST OF EUROPE: AI IN PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 181
TABLE 117 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 183
TABLE 118 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING,
2023–2030 (USD MILLION) 183
TABLE 119 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION,
2023–2030 (USD MILLION) 184
TABLE 120 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 184
TABLE 121 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 185
TABLE 122 ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 185
TABLE 123 CHINA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 186
TABLE 124 CHINA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 186
TABLE 125 CHINA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 187
TABLE 126 CHINA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 187
TABLE 127 CHINA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 188
TABLE 128 JAPAN: CANCER INCIDENCE, BY CANCER TYPE, 2020 VS. 2040 189
TABLE 129 JAPAN: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 189
TABLE 130 JAPAN: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 190
TABLE 131 JAPAN: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 190
TABLE 132 JAPAN: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 191
TABLE 133 JAPAN: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 191
TABLE 134 INDIA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 192
TABLE 135 INDIA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 193
TABLE 136 INDIA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 193
TABLE 137 INDIA: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 194
TABLE 138 INDIA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 194
TABLE 139 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY OFFERING,
2023–2030 (USD MILLION) 195
TABLE 140 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY FUNCTION,
2023–2030 (USD MILLION) 196
TABLE 141 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 196
TABLE 142 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 197
TABLE 143 REST OF ASIA PACIFIC: AI IN PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 197
TABLE 144 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY COUNTRY/REGION,
2023–2030 (USD MILLION) 199
TABLE 145 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING,
2023–2030 (USD MILLION) 199
TABLE 146 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION,
2023–2030 (USD MILLION) 200
TABLE 147 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 200
TABLE 148 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 201
TABLE 149 LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 201
TABLE 150 BRAZIL: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 202
TABLE 151 BRAZIL: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 202
TABLE 152 BRAZIL: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 203
TABLE 153 BRAZIL: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 203
TABLE 154 BRAZIL: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 204
TABLE 155 MEXICO: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 205
TABLE 156 MEXICO: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 205
TABLE 157 MEXICO: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 206
TABLE 158 MEXICO: AI IN PATHOLOGY MARKET, BY USE CASE, 2023–2030 (USD MILLION) 206
TABLE 159 MEXICO: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 207
TABLE 160 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY OFFERING,
2023–2030 (USD MILLION) 208
TABLE 161 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY FUNCTION,
2023–2030 (USD MILLION) 208
TABLE 162 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 209
TABLE 163 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 209
TABLE 164 REST OF LATIN AMERICA: AI IN PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 210
TABLE 165 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY REGION,
2023–2030 (USD MILLION) 211
TABLE 166 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING,
2023–2030 (USD MILLION) 211
TABLE 167 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION,
2023–2030 (USD MILLION) 212
TABLE 168 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 212
TABLE 169 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 213
TABLE 170 MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 213
TABLE 171 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY OFFERING,
2023–2030 (USD MILLION) 214
TABLE 172 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY FUNCTION,
2023–2030 (USD MILLION) 215
TABLE 173 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK,
2023–2030 (USD MILLION) 215
TABLE 174 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 216
TABLE 175 GCC COUNTRIES: AI IN PATHOLOGY MARKET, BY END USER,
2023–2030 (USD MILLION) 216
TABLE 176 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 217
TABLE 177 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY FUNCTION, 2023–2030 (USD MILLION) 217
TABLE 178 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2023–2030 (USD MILLION) 218
TABLE 179 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY USE CASE,
2023–2030 (USD MILLION) 218
TABLE 180 REST OF MIDDLE EAST & AFRICA: AI IN PATHOLOGY MARKET, BY END USER, 2023–2030 (USD MILLION) 219
TABLE 181 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES 221
TABLE 182 AI IN PATHOLOGY MARKET: DEGREE OF COMPETITION 224
TABLE 183 OFFERING FOOTPRINT 229
TABLE 184 USE CASE FOOTPRINT 230
TABLE 185 END USER FOOTPRINT 231
TABLE 186 REGION FOOTPRINT 232
TABLE 187 AI IN PATHOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 235
TABLE 188 AI IN PATHOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 235
TABLE 189 AI IN PATHOLOGY MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 237
TABLE 190 AI IN PATHOLOGY MARKET: DEALS, JANUARY 2021–APRIL 2025 239
TABLE 191 AI IN PATHOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021– APRIL 2025 241
TABLE 192 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 242
TABLE 193 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SERVICES OFFERED 243
TABLE 194 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021–APRIL 2025 244
TABLE 195 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 245
TABLE 196 F. HOFFMANN LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 246
TABLE 197 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−MARCH 2025 247
TABLE 198 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021−MARCH 2025 248
TABLE 199 HOLOGIC, INC.: COMPANY OVERVIEW 249
TABLE 200 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED 250
TABLE 201 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−APRIL 2025 251
TABLE 202 AKOYA BIOSCIENCES, INC.: COMPANY OVERVIEW 252
TABLE 203 AKOYA BIOSCIENCES, INC.: PRODUCT/SERVICES OFFERED 253
TABLE 204 AKOYA BIOSCIENCES, INC.: DEALS, JANUARY 2021−APRIL 2025 254
TABLE 205 AIFORIA TECHNOLOGIES PLC: COMPANY OVERVIEW 256
TABLE 206 AIFORIA TECHNOLOGIES PLC: PRODUCT/SERVICES OFFERED 257
TABLE 207 AIFORIA TECHNOLOGIES PLC: DEALS, JANUARY 2021−APRIL 2025 258
TABLE 208 INDICA LABS INC.: COMPANY OVERVIEW 261
TABLE 209 INDICA LABS INC.: PRODUCTS/SERVICES OFFERED 261
TABLE 210 INDICA LABS INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021−APRIL 2025 262
TABLE 211 INDICA LABS INC.: DEALS, JANUARY 2021−APRIL 2025 263
TABLE 212 INDICA LABS INC.: EXPANSIONS, JANUARY 2021–APRIL 2025 265
TABLE 213 OPTRASCAN: COMPANY OVERVIEW 266
TABLE 214 OPTRASCAN: PRODUCTS/SERVICES OFFERED 266
TABLE 215 OPTRASCAN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 267
TABLE 216 IBEX MEDICAL ANALYTICS LTD.: COMPANY OVERVIEW 268
TABLE 217 IBEX MEDICAL ANALYTICS LTD.: PRODUCTS/SERVICES OFFERED 268
TABLE 218 IBEX MEDICAL ANALYTICS LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021–APRIL 2025 269
TABLE 219 IBEX MEDICAL ANALYTICS LTD: DEALS, JANUARY 2021–APRIL 2025 270
TABLE 220 MINDPEAK GMBH: COMPANY OVERVIEW 272
TABLE 221 MINDPEAK GMBH: PRODUCTS/SERVICES OFFERED 272
TABLE 222 MINDPEAK GMBH: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–APRIL 2025 273
TABLE 223 MINDPEAK GMBH: DEALS, JANUARY 2021–APRIL 2025 273
TABLE 224 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 274
TABLE 225 TRIBUN HEALTH: COMPANY OVERVIEW 275
TABLE 226 TRIBUN HEALTH: PRODUCTS/SERVICES OFFERED 275
TABLE 227 TRIBUN HEALTH: DEALS, JANUARY 2021–APRIL 2025 276
TABLE 228 TECHCYTE, INC.: COMPANY OVERVIEW 277
TABLE 229 TECHCYTE, INC.: PRODUCTS/SERVICES OFFERED 277
TABLE 230 TECHCYTE, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–APRIL 2025 278
TABLE 231 TECHCYTE, INC.: DEALS, JANUARY 2021–APRIL 2025 278
TABLE 232 TECHCYTE, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 279
TABLE 233 DEEP BIO INC.: COMPANY OVERVIEW 280
TABLE 234 DEEP BIO INC.: PRODUCTS/SERVICES OFFERED 280
TABLE 235 DEEP BIO INC.: DEALS, JANUARY 2021–APRIL 2025 281
TABLE 236 LUMEA INC.: COMPANY OVERVIEW 282
TABLE 237 LUMEA INC.: PRODUCTS/SERVICES OFFERED 282
TABLE 238 LUMEA INC.: DEALS, JANUARY 2021–APRIL 2025 283
TABLE 239 VISIOPHARM: COMPANY OVERVIEW 284
TABLE 240 VISIOPHARM: PRODUCTS/SERVICES OFFERED 284
TABLE 241 VISIOPHARM: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–APRIL 2025 285
TABLE 242 VISIOPHARM: EXPANSIONS, JANUARY 2021– APRIL 2025 285
TABLE 243 AETHERAI: COMPANY OVERVIEW 287
TABLE 244 AETHERAI: PRODUCTS/SERVICES OFFERED 287
TABLE 245 AETHERAI: DEALS, JANUARY 2021– APRIL 2025 288
TABLE 246 AIOSYN: COMPANY OVERVIEW 289
TABLE 247 AIOSYN: PRODUCTS/SERVICES OFFERED 289
TABLE 248 AIOSYN: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–APRIL 2025 290
TABLE 249 AIOSYN: DEALS, JANUARY 2021–APRIL 2025 291
TABLE 250 AIOSYN: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 291
TABLE 251 PAIGE AI, INC.: COMPANY OVERVIEW 292
TABLE 252 PAIGE AI, INC.: PRODUCTS/SERVICES OFFERED 292
TABLE 253 PAIGE AI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021– APRIL 2025 293
TABLE 254 PAIGE AI, INC.: DEALS, JANUARY 2021–APRIL 2025 295
TABLE 255 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 295
TABLE 256 PROSCIA, INC.: COMPANY OVERVIEW 296
TABLE 257 PROSCIA, INC.: PRODUCTS/SERVICES OFFERED 296
TABLE 258 PROSCIA, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–APRIL 2025 297
TABLE 259 PROSCIA, INC.: DEALS, JANUARY 2021–APRIL 2025 298
TABLE 260 PROSCIA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–APRIL 2025 298
TABLE 261 PATHAI, INC.: COMPANY OVERVIEW 299
TABLE 262 PATHAI, INC.: PRODUCTS/SERVICES OFFERED 299
TABLE 263 PATHAI, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–APRIL 2025 300
TABLE 264 PATHAI, INC.: DEALS, JANUARY 2021–APRIL 2025 301
TABLE 265 TEMPUS LABS, INC.: COMPANY OVERVIEW 303
TABLE 266 TEMPUS LABS, INC.: PRODUCTS/SERVICES OFFERED 304
TABLE 267 TEMPUS LABS, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS,
JANUARY 2021–APRIL 2025 304
TABLE 268 KONFOONG BIOINFORMATION TECH CO., LTD.: COMPANY OVERVIEW 305
TABLE 269 DOMORE DIAGNOSTICS AS: COMPANY OVERVIEW 306
TABLE 270 QRITIVE: COMPANY OVERVIEW 306
TABLE 271 DEEPPATH: COMPANY OVERVIEW 307
TABLE 272 4D PATH INC.: COMPANY OVERVIEW 308
LIST OF FIGURES
FIGURE 1 RESEARCH DESIGN 33
FIGURE 2 KEY PRIMARY SOURCES 36
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 37
FIGURE 4 MARKET SIZE ESTIMATION PROCESS 38
FIGURE 5 KEY INSIGHTS FROM INDUSTRY EXPERTS 39
FIGURE 6 BOTTOM-UP APPROACH: END USER SPENDING ON AI IN PATHOLOGY 40
FIGURE 7 AI IN PATHOLOGY MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030) 41
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42
FIGURE 9 TOP-DOWN APPROACH 43
FIGURE 10 DATA TRIANGULATION METHODOLOGY 44
FIGURE 11 AI IN PATHOLOGY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 47
FIGURE 12 AI IN PATHOLOGY MARKET, BY NEURAL NETWORK, 2025 VS. 2030 (USD MILLION) 48
FIGURE 13 AI IN PATHOLOGY MARKET, BY USE CASE, 2025 VS. 2030 (USD MILLION) 48
FIGURE 14 AI IN PATHOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 49
FIGURE 15 AI IN PATHOLOGY MARKET: GEOGRAPHIC SNAPSHOT 50
FIGURE 16 DEVELOPMENT OF CONVOLUTIONAL NEURAL NETWORKS (CNNS) AND AI LEARNING MODELS TO PROPEL MARKET 51
FIGURE 17 NORTH AMERICA TO LEAD MARKET DURING FORECAST PERIOD 52
FIGURE 18 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT AND CHINA ACCOUNTED FOR SIGNIFICANT SHARE IN 2024 53
FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 54
FIGURE 20 AI IN PATHOLOGY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 55
FIGURE 21 HEALTHCARE BREACHES REPORTED TO US DEPARTMENT OF
HEALTH AND HUMAN SERVICES (SEPTEMBER 2024) 62
FIGURE 22 TRENDS & DISRUPTIONS IMPACTING CUSTOMER BUSINESS 63
FIGURE 23 ECOSYSTEM ANALYSIS 65
FIGURE 24 VALUE CHAIN ANALYSIS 67
FIGURE 25 EUROPE: IVDR TIMELINE 73
FIGURE 26 PORTER’S FIVE FORCES 76
FIGURE 27 NUMBER OF PATENTS PUBLISHED, JANUARY 2017−APRIL 2025 78
FIGURE 28 NUMBER OF PATENT DOCUMENTS, BY JURISDICTION 79
FIGURE 29 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS),
JANUARY 2017–APRIL 2025 80
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER 82
FIGURE 31 KEY BUYING CRITERIA, BY END USER 83
FIGURE 32 FUNDING ACTIVITIES IN AI IN PATHOLOGY MARKET 87
FIGURE 33 MARKET POTENTIAL OF AI/GENERATIVE AI IN PATHOLOGY 89
FIGURE 34 IMPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY,
2020–2023 (USD) 94
FIGURE 35 EXPORT DATA FOR HS CODE 9011-COMPLIANT PRODUCTS, BY COUNTRY,
2020–2023 (USD THOUSAND) 95
FIGURE 36 NORTH AMERICA: AI IN PATHOLOGY MARKET SNAPSHOT 150
FIGURE 37 ASIA PACIFIC: AI IN PATHOLOGY MARKET SNAPSHOT 182
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS, 2020−2024 (USD MILLION) 223
FIGURE 39 AI IN PATHOLOGY MARKET: MARKET SHARE ANALYSIS (2024) 224
FIGURE 40 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 227
FIGURE 41 AI IN PATHOLOGY MARKET: COMPANY FOOTPRINT 228
FIGURE 42 AI IN PATHOLOGY MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2024 234
FIGURE 43 EV/EBITDA OF KEY VENDORS 236
FIGURE 44 YTD PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
AI IN PATHOLOGY VENDORS 236
FIGURE 45 BRAND/PRODUCT COMPARISON 237
FIGURE 46 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024) 243
FIGURE 47 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 246
FIGURE 48 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 250
FIGURE 49 AKOYA BIOSCIENCES, INC.: COMPANY SNAPSHOT (2023) 253
FIGURE 50 AIFORIA TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024) 256
FIGURE 51 TEMPUS: COMPANY SNAPSHOT (2024) 303
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 高圧洗浄機市場 – 2030年までの世界予測 2025-06-12
- 装甲車両市場 – 2030年までの世界予測 2025-06-12
- 工業用ゴム市場 – 2030年までの世界予測 2025-06-12
- 追跡・トレースソリューション市場 – 2030年までの世界予測 2025-06-12
- エクソソーム研究市場 – 2030年までの世界予測 2025-06-10